

# Jenna Rossoff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7406541/publications.pdf>

Version: 2024-02-01

23  
papers

589  
citations

759055

12  
h-index

713332

21  
g-index

24  
all docs

24  
docs citations

24  
times ranked

770  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 81-112.	2.3	102
2	Noninvasive Diagnosis of Infection Using Plasma Next-Generation Sequencing: A Single-Center Experience. Open Forum Infectious Diseases, 2019, 6, .	0.4	84
3	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. Journal of Clinical Oncology, 2022, 40, 945-955.	0.8	79
4	Cell-free DNA next-generation sequencing successfully detects infectious pathogens in pediatric oncology and hematopoietic stem cell transplant patients at risk for invasive fungal disease. Pediatric Blood and Cancer, 2019, 66, e27734.	0.8	73
5	Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Advances, 2022, 6, 1961-1968.	2.5	47
6	Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Advances, 2022, 6, 600-610.	2.5	32
7	Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC). Blood, 2020, 136, 14-15.	0.6	25
8	Benign course of SARS-CoV-2 infection in a series of pediatric oncology patients. Pediatric Blood and Cancer, 2020, 67, e28504.	0.8	22
9	Experience with ponatinib in paediatric patients with leukaemia. British Journal of Haematology, 2020, 189, 363-368.	1.2	21
10	Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Advances, 2022, 6, 4251-4255.	2.5	20
11	Access to Technology and Preferences for an mHealth Intervention to Promote Medication Adherence in Pediatric Acute Lymphoblastic Leukemia: Approach Leveraging Behavior Change Techniques. Journal of Medical Internet Research, 2021, 23, e24893.	2.1	18
12	Applying the COMB model to patient-reported barriers to medication adherence in pediatric acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28216.	0.8	14
13	Appendectomy Versus Observation for Appendicitis in Neutropenic Children With Cancer. Pediatrics, 2021, 147, e2020027797.	1.0	10
14	Cost analysis of bronchoalveolar lavage and respiratory tract biopsies in the diagnosis and management of suspected invasive fungal infection in children with cancer or who have undergone stem cell transplant. Pediatric Blood and Cancer, 2019, 66, e27598.	0.8	9
15	Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series. Pediatric Blood and Cancer, 2021, 68, e29261.	0.8	9
16	Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release. Blood, 2020, 136, 42-44.	0.6	8
17	Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood, 2021, 138, 2138-2142.	0.6	5
18	Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. Pediatric Blood and Cancer, 2021, 68, e29087.	0.8	4

#	ARTICLE	IF	CITATIONS
19	High-dose chemotherapy and autologous hematopoietic stem-cell rescue for treatment of relapsed and refractory Wilms tumor: Re-evaluating outcomes. <i>Pediatric Hematology and Oncology</i> , 2018, 35, 316-321.	0.3	3
20	Spontaneous remission in congenital leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2271-2272.	0.6	3
21	Impact of myosteatorsis in survivors of childhood acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 3097-3098.	0.6	1
22	Initial Management of Fever and Neutropenia: A Practical Approach. <i>Clinical Pediatric Emergency Medicine</i> , 2018, 19, 145-152.	0.4	0
23	Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10016-10016.	0.8	0